|
WO2009045412A2
|
|
Methods of treatment using modified plasminogen activator inhibitor type-1 molecules
|
|
EP1962091A1
|
|
Methods and kits for detecting and measuring ADAMTS13/FX1 complexes
|
|
EP1960395A1
|
|
Plasminogen activator inhibitor-1 inhibitors
|
|
WO2007051314A1
|
|
Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
|
|
WO2007044892A2
|
|
Upar-binding molecule-drug conjugates and uses thereof
|
|
WO2006046108A2
|
|
Diagnosis of male infertility by measuring tissue factor pathway inhibitor
|
|
EP1920068A1
|
|
Lupus anticoagulant testing
|
|
US2007026467A1
|
|
Lupus anticoagulant testing
|
|
US2006014233A1
|
|
Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
|
|
WO2006019379A1
|
|
Methods for measuring adamts13 activity and protein on platelets and in plasma
|
|
WO2004019882A2
|
|
METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE TAFIa ACTIVITY, COMPOUNDS, AND METHODS OF USING THE COMPOUNDS
|
|
EP1539991A2
|
|
Diagnostic assay for thrombin-activatable fibrinolysis inhibitor (tafi)
|
|
EP1563302A2
|
|
Methods for selecting treatment regimens and predicting outcomes in cancer patients
|
|
US6808927B2
|
|
Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (TAFI) and methods of use thereof
|
|
US6077508A
|
|
Urokinase plasminogen activator receptor as a target for diagnosis of metastases
|
